GlassScriptPhysician profile
Lesley Clarkloeser
NPI 1265429583
$39,606.08
in general payments reported to CMS, 2019-2025
31 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $4,060 · 2021: $277 · 2022: $615 · 2023: $1,480 · 2024: $2,161 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $4,460 · Education: $97.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,500.00 |
| Food and Beverage | $4,459.72 |
| Education | $97.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16,150.88 | 2019-2024 | |
| Revance Therapeutics, INC. | $14,463.79 | 2024-2025 | Daxxify, Daxi |
| Allergan, INC. | $3,155.49 | 2019-2020 | |
| Merz North America, INC. | $836.01 | 2021-2024 | Xeomin |
| Abbvie INC. | $723.11 | 2019-2025 | Rinvoq |
| Galderma Laboratories, L.P. | $683.19 | 2019-2025 | Nemluvio |
| Janssen Biotech, INC. | $515.00 | 2019-2025 | Tremfya |
| Dermavant Sciences, INC. | $423.81 | 2022-2024 | Vtama |
| Genzyme Corporation | $281.39 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $245.10 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $209.67 | 2021-2025 | Absorica Ld, Winlevi |
| Almirall LLC | $193.44 | 2019-2025 | Seysara, Klisyri |
| Leo Pharma INC. | $183.72 | 2019-2024 | Adbry |
| Dermira, INC. | $180.96 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $162.86 | 2022-2024 | Sotyktu |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $157.55 | 2020 | |
| Amgen INC. | $141.34 | 2020-2025 | Otezla |
| Incyte Corporation | $120.27 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $116.53 | 2021-2025 | |
| Lilly USA, LLC | $115.47 | 2019-2024 | Taltz, Ebglyss |
| Mayne Pharma Commercial LLC | $113.89 | 2019-2023 | |
| Biofrontera INC. | $105.14 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $87.39 | 2024-2025 | Dupixent |
| Journey Medical Corporation | $67.66 | 2022-2025 | |
| Celgene Corporation | $45.07 | 2019 | |
| Epi Health, LLC | $44.12 | 2021-2022 | |
| Botanix Sb INC | $37.68 | 2025 | Sofdra |
| Aclaris Therapeutics, INC. | $18.55 | 2019 | |
| Tempus Ai, INC | $16.18 | 2024 | Merlin Test |
| Organon LLC | $10.82 | 2025 | Vtama |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Clarkloeser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.